880-881 / 2437
NOA-4 trial
• Equal response to RT or chemotherapy (PCV or TMZ) as single modality
• Better prognosis for patients showing oligodendroglial component (1p/19q co-deletion) and MGMT
methylation
1
• A retrospective analysis of the same trial revealed that the addition of chemotherapy was beneficial
for IDH1/2 mutated, or IDH1/2 wild type and MGMT methylated
2
1.
Wick, et al. JCO, 2009
2.
Wick, et al. Neurol, 2013